Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSINASDAQ:MXCTNASDAQ:NRCNASDAQ:ZY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$2.78-2.1%$2.88$2.01▼$6.33$354.61M2.062.81 million shs2.22 million shsMXCTMaxCyte$2.20-3.1%$2.45$2.10▼$5.20$234.12M1.27613,857 shs912,311 shsNRCNational Research$16.04+0.1%$12.91$9.76▼$27.07$365.47M0.3896,196 shs103,347 shsZYZymergen$2.43$2.52$1.10▼$12.42$253.58M1.691.23 million shs85 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-2.11%-8.25%-4.47%-11.46%-43.95%MXCTMaxCyte-3.08%+2.33%0.00%-33.13%-56.00%NRCNational Research+0.06%+6.79%+19.79%+8.16%-36.73%ZYZymergen0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABSIAbsci2.1249 of 5 stars3.51.00.00.02.71.70.6MXCTMaxCyte3.5895 of 5 stars3.55.00.00.02.02.51.3NRCNational Research1.594 of 5 stars0.02.01.70.01.92.51.3ZYZymergenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 3.00Buy$8.40202.16% UpsideMXCTMaxCyte 3.00Buy$7.50240.91% UpsideNRCNational Research 0.00N/AN/AN/AZYZymergen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZY, ABSI, NRC, and MXCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/16/2025ABSIAbsciKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $9.004/9/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/20/2025ABSIAbsciGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025ABSIAbsciHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/19/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$4.82M73.65N/AN/A$1.90 per share1.46MXCTMaxCyte$37.68M6.21N/AN/A$2.23 per share0.99NRCNational Research$141.30M2.59$1.48 per share10.81$2.02 per share7.94ZYZymergen$16.74M15.15N/AN/A$3.99 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$110.57M-$0.92N/AN/AN/A-2,321.56%-46.56%-39.74%8/13/2025 (Estimated)MXCTMaxCyte-$37.92M-$0.40N/AN/AN/A-78.36%-16.00%-13.93%8/5/2025 (Estimated)NRCNational Research$24.78M$1.0315.28∞N/A17.32%66.52%20.00%7/28/2025 (Estimated)ZYZymergen-$361.79M-$3.55N/AN/AN/A-2,508.94%-93.37%-61.14%N/ALatest ZY, ABSI, NRC, and MXCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ABSIAbsci-$0.23-$0.21+$0.02-$0.21$1.07 million$1.18 million5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million4/28/2025Q1 2025NRCNational ResearchN/A$0.25N/A$0.25N/A$33.55 million3/18/2025Q4 2024ABSIAbsci-$0.22-$0.25-$0.03-$0.25$1.77 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/ANRCNational Research$0.482.99%N/A46.60%N/AZYZymergenN/AN/AN/AN/AN/ALatest ZY, ABSI, NRC, and MXCT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/25/2025NRCNational Researchquarterly$0.124.1%6/27/20256/27/20257/11/20253/24/2025NRCNational Researchquarterly$0.123.27%3/28/20253/28/20254/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsci0.015.635.63MXCTMaxCyteN/A9.819.22NRCNational Research1.300.470.47ZYZymergenN/A4.594.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%MXCTMaxCyte68.81%NRCNational Research47.26%ZYZymergen52.99%Insider OwnershipCompanyInsider OwnershipABSIAbsci10.49%MXCTMaxCyte3.30%NRCNational Research8.10%ZYZymergen11.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210127.56 million103.59 millionOptionableMXCTMaxCyte80106.42 million102.67 millionOptionableNRCNational Research49022.79 million23.01 millionOptionableZYZymergen502104.36 million92.15 millionNot OptionableZY, ABSI, NRC, and MXCT HeadlinesRecent News About These CompaniesThe California crisis in homeowners insurance has only one real solutionMarch 10, 2025 | msn.comHere's how much Sutter Health just spent on its new 12-acre campus in EmeryvilleFebruary 21, 2025 | bizjournals.comPublic Companies Update – October 2024 One-Minute ReadsNovember 14, 2024 | jdsupra.comThe Role of Massachusetts in Promoting Sustainable Biotech SolutionsOctober 27, 2024 | techbullion.comOptically Clear Resin Market Forecast: 6.1% CAGR to Drive Industry Growth, Driven by Demand in Electronics and Automotive SectorsOctober 25, 2024 | fmiblog.comSEC Charges Biotech Co. with Misleading IPO InvestorsOctober 3, 2024 | jdsupra.comSEC Penalizes Company for "Unsupported Hype"September 26, 2024 | jdsupra.comAdvanced Materials (AdMs) in Defense Thematic Intelligence Research ReportSeptember 18, 2024 | finance.yahoo.comArkeaBio: Vaccination is ‘the lowest cost and easiest to scale’ livestock methane reduction solutionSeptember 18, 2024 | agfundernews.comSEC charges Zymergen for “unsupported hype” in its IPOSeptember 18, 2024 | jdsupra.comTroubling Headlines for Emeryville Life Science SectorSeptember 15, 2024 | evilleeye.comAfter a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penaltySeptember 13, 2024 | endpts.comSEC Charges Zymergen Inc. With Misleading IPO Investors About Company’s Market Potential and Sales ProspectsSeptember 13, 2024 | msn.comSEC Charges Zymergen Inc. With Misleading IPO Investors About Company's Market Potential and Sales ProspectsSeptember 13, 2024 | newsfilecorp.comOhmium Announces Enakshi Singh as New Chief Financial OfficerAugust 27, 2024 | sg.finance.yahoo.comZymergen Investors Mostly Advance Claims Against Venture FundsAugust 16, 2024 | news.bloomberglaw.comGinkgo Bioworks Holdings, Inc. (DNA) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comAI biotechs Exscientia and Recursion agree $688m mergerAugust 8, 2024 | pharmaphorum.comGenerative AI in Biology Market Size and Trends in 2033May 24, 2024 | pharmiweb.comGinkgo Bioworks: Broken NarrativeMay 10, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZY, ABSI, NRC, and MXCT Company DescriptionsAbsci NASDAQ:ABSI$2.78 -0.06 (-2.11%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.80 +0.02 (+0.72%) As of 06/13/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.MaxCyte NASDAQ:MXCT$2.20 -0.07 (-3.08%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.21 +0.01 (+0.41%) As of 06/13/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.National Research NASDAQ:NRC$16.04 +0.01 (+0.06%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$16.04 0.00 (0.00%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.Zymergen NASDAQ:ZYZymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
